# US 2022/0033496 A1 · Anti-ilt4 antibodies and antigen-binding fragments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033496 A1
- Document ID: US20220033496A1
- Status: Published application
- Kind: A1
- Application number: 17/338,597
- Filed: 2021-06-03
- Published: 2022-02-03
- Earliest claimed: 2017-04-07
- Assignees: Merck Sharp & Dohme Corp.; Agenus Inc.
- Applicants: Merck Sharp & Dohme Corp.; Agenus Inc.
- Inventors: Milan BLANUSA; Barbara JOYCE-SHAIKH; Andrea Claudia SCHUSTER; Kornelia SCHULTZE; Luis A. ZUNIGA
- Web page: https://patentgrep.com/patent/US20220033496A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.

## Claims

### Claim 1

An antibody or antigen-binding fragment thereof that binds one or more amino acid residues in a human immunoglobulin-like transcript 4 (ILT4) epitope selected from the group consisting of LYREKKSASW (SEQ ID NO:59), TRIRPEL (SEQ ID NO:60), NGQF (SEQ ID NO:61), and HTGRYGCQ (SEQ ID NO:62) and protects the epitope from deuterium exchange in the presence of a deuterium source.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the ILT4 epitope is
LYREKKSASW.
(SEQ ID NO: 59)

### Claim 3 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the ILT4 epitope is
TRIRPEL.
(SEQ ID NO: 60)

### Claim 4 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the ILT4 epitope is
NGQF.
(SEQ ID NO: 61)

### Claim 5 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the ILT4 epitope is
HTGRYGCQ.
(SEQ ID NO: 62)

### Claim 6

An antibody or antigen-binding fragment thereof that competes with a reference antibody for binding to a human ILT4 epitope selected from the group consisting of LYREKKSASW (SEQ ID NO:59), TRIRPEL (SEQ ID NO:60), NGQF (SEQ ID NO:61), and HTGRYGCQ (SEQ ID NO:62), wherein the reference antibody comprises a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:2 and a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:7.

### Claim 7 (depends on 6)

The antibody or antigen-binding fragment thereof of claim 6, wherein the ILT4 epitope is
LYREKKSASW.
(SEQ ID NO: 59)

### Claim 8 (depends on 6)

The antibody or antigen-binding fragment thereof of claim 6, wherein the ILT4 epitope is
TRIRPEL.
(SEQ ID NO: 60)

### Claim 9 (depends on 6)

The antibody or antigen-binding fragment thereof of claim 6, wherein the ILT4 epitope is
NGQF.
(SEQ ID NO: 61)

### Claim 10 (depends on 6)

The antibody or antigen-binding fragment thereof of claim 6, wherein the ILT4 epitope is
HTGRYGCQ.
(SEQ ID NO: 62)

### Claim 11

An antibody or antigen-binding fragment thereof that binds human ILT4, comprising:
(1) a heavy chain variable domain comprising:
CDR-H1:
(SEQ ID NO: 16)
GYYWS,
CDR-H2:
(SEQ ID NO: 17)
EINHXGSTNYNPSLKS wherein X is S or A,
and
CDR-H3:
(SEQ ID NO: 18)
LPTRWVTTRYFDL;
and,
a light chain variable domain comprising:
CDR-L1:
(SEQ ID NO: 19)
TGSSSNIGAGYDVH.
CDR-L2:
(SEQ ID NO: 20)
GX1X2NRPS, wherein X1 is N, Q, E or D and
X2 is S or A,
and
CDR-L3:
(SEQ ID NO: 21)
QSFDNSLSAYV;
(2) a heavy chain variable domain comprising:
CDR-H1:
(SEQ ID NO: 22)
SYAIS,
CDR-H2:
(SEQ ID NO: 23)
GIIPIFGTANYAQKFQG,
and
CDR-H3:
(SEQ ID NO: 24)
YFX1X2SGWYKGGAFDI, wherein X1 is D or S and
X2 is S or A;
and,
a light chain variable domain comprising:
CDR-L1:
(SEQ ID NO: 25)
TLRSGINVDTYRIH,
CDR-L2:
(SEQ ID NO: 26)
YKSDSDKHQGS,
and
CDR-L3:
(SEQ ID NO: 27)
AIWYSSTWV;
(3) a heavy chain variable domain comprising:
CDR-H1:
(SEQ ID NO: 28)
SYAMH,
CDR-H2:
(SEQ ID NO: 29)
VISYDGSNKYYADSVKG,
and
CDR-H3:
(SEQ ID NO: 30)
VGEWIQLWSPFDY;
and,
a light chain variable domain comprising:
CDR-L1:
(SEQ ID NO: 31)
RASQGISSWLA,
CDR-L2:
(SEQ ID NO: 32)
AASSLQS,
and
CDR-L3:
(SEQ ID NO: 33)
QQYNSYPPT;
or
(4) a heavy chain variable domain comprising:
CDR-H1:
(SEQ ID NO: 34)
ELSMH,
CDR-H2:
(SEQ ID NO: 35)
GFDPEDGETIYAQKFQG,
and
CDR-H3:
(SEQ ID NO: 36)
AGPLYTIFGVVIIPDNWFDP;
and,
a light chain variable domain comprising:
CDR-L1:
(SEQ ID NO: 37)
TGSSSNIGAGYDVH,
CDR-L2:
(SEQ ID NO: 38)
GNSNRPS,
and
CDR-L3:
(SEQ ID NO: 39)
QSYDSSLSGSGVV.

### Claim 12 (depends on 11)

The antibody or antigen-binding fragment thereof of claim 11, comprising:
a heavy chain variable domain comprising:
CDR-H1:
GYYWS,
(SEQ ID NO: 16)
CDR-H2:
EINHAGSTNYNPSLKS,
(SEQ ID NO: 48)
and
CDR-H3:
LPTRWVTTRYFDL;
(SEQ ID NO: 18)
and,
a light chain variable domain comprising:
CDR-L1:
TGSSSNIGAGYDVH,
(SEQ ID NO: 19)
CDR-L2:
GDSNRPS,
(SEQ ID NO: 52)
and
CDR-L3:
QSFDNSLSAYV.
(SEQ ID NO: 21)

### Claim 13 (depends on 11)

The antibody or antigen-binding fragment thereof of claim 11, comprising:
a light chain immunoglobulin having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:3, 4, 5, 6, 7, 11, 13, 15, or 45, and/or
a heavy chain immunoglobulin having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:1, 2, 8, 9, 10, 12, 14, 44, 79, 80, 81, 82, 83, 84, 85, or 86.

### Claim 14 (depends on 11)

The antibody or antigen-binding fragment thereof of claim 11, comprising:
a light chain immunoglobulin comprising a light chain variable domain having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:70, 71, 72, 73, 58, 74, 75, 76, or 77, and/or
a heavy chain immunoglobulin comprising a heavy chain variable domain having at least 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:63, 57, 64, 65, 66, 67, 68, or 69.

### Claim 15 (depends on 11)

The antibody or antigen-binding fragment thereof of claim 11, comprising:
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:3, 4, 5, 6, 7, 11, 13, 15, or 45; and/or
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 1, 2, 8, 9, 10, 12, 14, 44, 79, 80, 81, 82, 83, 84, 85, or 86.

### Claim 16 (depends on 11)

The antibody or antigen-binding fragment thereof of claim 11, comprising:
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:70, 71, 72, 73, 58, 74, 75, 76, or 77, and/or
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:63, 57, 64, 65, 66, 67, 68, or 69.

### Claim 17 (depends on 11)

The antibody or antigen-binding fragment thereof of claim 11, comprising:
(1)
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 1 or 79; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 3;
(2)
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 2 or 80; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 4;
(3)
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 2 or 80; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 5;
(4)
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 2 or 80; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 6;
(5)
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 2 or 80; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 7;
(6)
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 2 or 80; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 3;
(7)
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 8 or 82; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 11;
(8)
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 9 or 83; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 11;
(9)
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 10 or 84; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 11;
(10)
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 12 or 85; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 13; or
(11)
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 14 or 86; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 15.

### Claim 18 (depends on 11)

The antibody or antigen-binding fragment thereof of claim 11, comprising:
(1)
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:63; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:70;
(2)
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:57; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:71;
(3)
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:57; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:72;
(4)
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:57; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:73;
(5)
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:57; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:58;
(6)
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:57; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:70;
(7)
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:64; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:74;
(8)
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:65; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:74;
(9)
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:66; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:74;
(10)
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:67; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:75; or
(11)
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:68; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:76.

### Claim 19 (depends on 11)

The antibody or antigen-binding fragment thereof of claim 11, comprising:
a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:57; and
a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO:58.

### Claim 20 (depends on 11)

The antibody or antigen-binding fragment thereof of claim 11, comprising:
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:2; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:7.

### Claim 21 (depends on 11)

The antibody or antigen-binding fragment thereof of claim 11, comprising:
a heavy chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:80; and
a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO:7.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The antibody or antigen-binding fragment thereof of any one of claims 1-21, wherein the antibody or antigen-binding fragment thereof is glycosylated with engineered yeast N-linked glycans or CHO N-linked glycans.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any of claims 1-22.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, further comprises a therapeutic agent.

### Claim 25 (depends on 23, 24)

The pharmaceutical composition of claim 23 or 24, further comprises a pharmaceutically acceptable carrier.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A polynucleotide comprising nucleotide sequence encoding a VH, a VL, both a VH and a VL, a heavy chain immunoglobulin, a light chain immunoglobulin, or both a heavy chain and a light chain immunoglobulin of the antibody or antigen-binding fragment according to any one of the claims 1-21.

### Claim 27 (depends on 26)

A vector comprising the polynucleotide of claim 26.

### Claim 28 (depends on 26, 27)

A host cell comprising the polynucleotide of claim 26 or the vector of claim 27.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A method for blocking binding of ILT4 to HLA-G, HLA-A, HLA-B and/or HLA-F in a human subject in need thereof comprising administering to the human subject an effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1-22.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A method of treating a cancer in a human subject in need thereof, comprising administering to the human subject an effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1-22.

### Claim 31 (depends on 29, 30)

The method of claim 29 or 30, further comprises performing a therapeutic procedure and/or administering a therapeutic agent to the human subject.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 28)

A method of producing the antibody or antigen-binding fragment thereof of any one of claims 1-22, comprising culturing the host cell of claim 28 to express the antibody or antigen-binding fragment thereof.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26)

A method of producing the antibody or antigen-binding fragment thereof of any one of claims 1-22, comprising expressing the polynucleotide of claim 26.

### Claim 34 (depends on 32, 33)

An antibody or antigen-binding fragment thereof that binds to human ILT4 which is a product of the method of claim 32 or 33.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A method for detecting an ILT4 peptide or fragment thereof in a sample, comprising contacting the sample with the antibody or antigen-binding fragment thereof of any one of claims 1-22 and detecting the presence of a complex between the antibody or antigen-binding fragment thereof and the ILT4 peptide or fragment thereof; wherein detection of the complex indicates the presence of the ILT4 peptide or fragment thereof.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

Use of the antibody or antigen-binding fragment thereof of any one of claims 1-22 for the treatment of cancer.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The antibody or antigen-binding fragment thereof of any one of claims 1-22 for use in treating cancer.

### Claim 38

An antibody that consists of two heavy chains and two light chains, wherein each light chain comprises the amino acid sequence set forth in SEQ ID NO:58 and each heavy chain comprises the amino acid sequence set forth in SEQ ID NO:57.

### Claim 39 (depends on 38)

The antibody of claim 38, wherein the light chain further comprises the amino acid sequence set forth in SEQ ID NO:90 and/or the heavy chain further comprises the amino acid sequence set forth in SEQ ID NO:89.

### Claim 40

An antibody that consists of two heavy chains and two light chains, wherein each light chain comprises the amino acid sequence set forth in SEQ ID NO:7 and each heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2.

### Claim 41

An antibody that consists of two heavy chains and two light chains, wherein each light chain consists of the amino acid sequence set forth in SEQ ID NO:7 and each heavy chain consists of the amino acid sequence set forth in SEQ ID NO:2.

### Claim 42

A pharmaceutical composition comprising: (i) an antibody that consists of two heavy chains and two light chains, wherein each light chain consists of the amino acid sequence set forth in SEQ ID NO:7 and each heavy chain consists of the amino acid sequence set forth in SEQ ID NO:2, and (ii) pembrolizumab.
